Protagonist Therapeutics, Inc

For the period ended Sep 30, 2026. Filed Nov 6, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 6, 2026

PTGX$136.26+0.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

(In thousands, except share data)


· · · · · · · · Accumulated · · · ·
· · · · · · Additional · · Other · · · · Total
· · Common · · Treasury · · Paid-In · · Comprehensive · · Accumulated · · Stockholders’
· · Stock · · Stock · · Capital · · (Loss) Income · · Deficit · · Equity
Three months ended September 30, 2026 · · Shares · · Amount · · Shares · · Amount · · · · · · · · · · ·
Balance at June 30, 2026	64,672,032	$1	—	$—	$1,146,409	$(828)	$(304,039)	$841,543
Issuance of common stock under equity incentive and employee stock purchase plans	584,120	—	—	—	15,247	—	—	15,247
Repurchase of common stock	—	—	(40,560)	(5,791)	—	—	—	(5,791)
Stock-based compensation expense		—		—	14,363	—	—	14,363
Other comprehensive loss	—	—	—	—	—	(467)	—	(467)
Net income	—	—	—	—	—	—	220,015	220,015
Balance at September 30, 2026	65,256,152	$1	(40,560)	$(5,791)	$1,176,019	$(1,295)	$(84,024)	$1,084,910

· · · · · · · · · · · · · · · · · · · · · ·
· · · · · · · · Accumulated · · · ·
· · · · · · Additional · · Other · · · · Total
· · Common · · Treasury · · Paid-In · · Comprehensive · · Accumulated · · Stockholders’
· · Stock · · Stock · · Capital · · (Loss) Income · · Deficit · · Equity
Three months ended September 30, 2025 · · Shares · · Amount · · Shares · · Amount · · · · · · · · · · ·
Balance at June 30, 2025	62,107,572	$1	—	$—	$1,054,980	$(15)	$(386,948)	$668,018
Issuance of common stock under equity incentive and employee stock purchase plans	339,530	—	—	—	5,659	—	—	5,659
Stock-based compensation expense	—	—	—	—	10,559	—	—	10,559
Other comprehensive income	—	—	—	—	—	540	—	540
Net loss	—	—	—	—	—	—	(39,339)	(39,339)
Balance at September 30, 2025	62,447,102	$1	—	$—	$1,071,198	$525	$(426,287)	$645,437

PROTAGONIST THERAPEUTICS, INC.

Condensed Consolidated Statements of Stockholders’ Equity

(In thousands, except share data)


· · · · · · · · Accumulated · · · ·
· · · · · · Additional · · Other · · · · Total
· · Common · · Treasury · · Paid-In · · Comprehensive · · Accumulated · · Stockholders’
· · Stock · · Stock · · Capital · · (Loss) Income · · Deficit · · Equity
Nine months ended September 30, 2026 · · Shares · · Amount · · Shares · · Amount · · · · · · · · · · ·
Balance at December 31, 2025	62,577,897	$1	—	$—	$1,084,736	$641	$(470,671)	$614,707
Issuance of common stock under equity incentive and employee stock purchase plans	2,678,255	—	—	—	48,363	—	—	48,363
Repurchase of common stock	—	—	(40,560)	(5,791)	—	—	—	(5,791)
Stock-based compensation expense	—	—	—	—	42,920	—	—	42,920
Other comprehensive loss	—	—	—	—	—	(1,936)	—	(1,936)
Net income	—	—	—	—	—	—	386,647	386,647
Balance at September 30, 2026	65,256,152	$1	(40,560)	$(5,791)	$1,176,019	$(1,295)	$(84,024)	$1,084,910


· · · · · · · · Accumulated · · · ·
· · · · · · Additional · · Other · · · · Total
· · Common · · Treasury · · Paid-In · · Comprehensive · · Accumulated · · Stockholders’
· · Stock · · Stock · · Capital · · (Loss) Income · · Deficit · · Equity
Nine months ended September 30, 2025 · · Shares · · Amount · · Shares · · Amount · · · · · · · · · · ·
Balance at December 31, 2024	61,035,139	$1	—	$—	$1,015,898	$(82)	$(340,522)	$675,295
Issuance of common stock under equity incentive and employee stock purchase plans	1,424,599	—	—	—	20,506	—	—	20,506
Shares withheld for net settlement of tax withholding upon vesting of restricted stock units	(12,636)	—	—	—	(479)	—	—	(479)
Stock-based compensation expense	—	—	—	—	35,273	—	—	35,273
Other comprehensive income	—	—	—	—	—	607	—	607
Net loss	—	—	—	—	—	—	(85,765)	(85,765)
Balance at September 30, 2025	62,447,102	$1	—	$—	$1,071,198	$525	$(426,287)	$645,437

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.